NEW YORK--(BUSINESS WIRE)--

Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Michigan on behalf of all persons or entities who purchased or otherwise acquired Esperion Therapeutics, Inc. (NASDAQ: ESPR) securities between February 22, 2017 and May 2, 2018 (the “Class Period”). Investors have until July 6, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) Esperion's cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and (ii) as a result of the foregoing, Esperion's public statements were materially false and misleading at all relevant times.

If you purchased or otherwise acquired Esperion securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Esperion Therapeutics, Inc. lawsuit, please go to https://bespc.com/esperion/. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180508006350/en/